rs640561 — LRRIQ3

LRRIQ3 — A Genetic Signal in the Opioid Prescription Landscape

Most genetic research on opioid response focuses on the mu-opioid receptor gene OPRM1 or enzymes that metabolize specific drugs. But a 2021 genome-wide association study of problematic opioid prescription use pointed to an unexpected locus on chromosome 1 — a variant near LRRIQ3¹¹ LRRIQ3
Leucine-Rich Repeat and IQ domain-Containing 3; gene ID 127255 on the minus strand of chromosome 1, encoding a 624 amino acid protein with roles in protein-protein interactions and calcium signaling in neural circuits. The T allele of rs640561 was the first genome-wide significant non-OPRM1 signal identified specifically for the misuse of prescription opioids.

The Mechanism

rs640561 sits roughly 555 kilobases upstream of LRRIQ3 in a region annotated as intergenic at chromosome 1, position 73,470,677 (GRCh38). It falls within an intronic region of an uncharacterized RNA gene (LOC105378801), and is best understood as a regulatory tag variant²² regulatory tag variant
A variant that marks, through linkage disequilibrium, a nearby functional change in gene expression rather than altering a protein directly influencing LRRIQ3 expression or a co-regulated gene in this chromosomal neighborhood.

LRRIQ3 encodes a protein characterized by tandem leucine-rich repeat domains³³ leucine-rich repeat domains
LRR domains mediate protein-protein interactions and are found in many immune and neural signaling proteins; they form a curved solenoid structure that serves as a scaffold for binding partners and an IQ calmodulin-binding motif⁴⁴ IQ calmodulin-binding motif
IQ motifs bind calmodulin in a calcium-independent manner, enabling calcium-regulated signaling; they are common in proteins that modulate synaptic plasticity and neurotransmission. This architecture positions LRRIQ3 as a potential scaffolding protein in neural calcium-signaling cascades — the same cascades that regulate synaptic plasticity and opioid receptor internalization after ligand binding. The exact function of LRRIQ3 in pain circuits is under active investigation.

The Evidence

The index study, Sanchez-Roige et al. (2021)⁵⁵ Sanchez-Roige et al. (2021)
Genome-wide association study of problematic opioid prescription use in 132,113 23andMe research participants of European ancestry. Molecular Psychiatry, 26(11): 6209-6217., enrolled 27,805 cases and 104,308 controls and defined the phenotype as using prescription opioids "not as prescribed." rs640561-T reached genome-wide significance at p = 4×10⁻⁸. The study also found strong genetic correlations between problematic opioid use and opioid use disorder (rg = 0.64–0.80), alcohol dependence (rg = 0.74), chronic pain (rg = 0.42), and major depressive disorder (rg = 0.44), placing the LRRIQ3 locus in a broader landscape of substance use and pain vulnerability.

A 2025 replication attempt⁶⁶ 2025 replication attempt
Annis et al. tested 80 unique genetic signals from the literature in 40,000 non-Hispanic European-ancestry surgical patients from the Michigan Genomics Initiative (3,198 cases with persistent postoperative opioid use). Genetic Epidemiology, 2025. found only nominal significance for rs640561 (p = 0.015) that did not survive correction for multiple testing. The authors concluded that OPRM1 variants are the primary genetic driver of persistent opioid use, and that most candidate loci — including rs640561 — showed limited reproducibility across phenotype definitions and ancestry groups.

Evidence level is therefore emerging: a single large GWAS with genome-wide significance, partial replication at nominal level only, and no independent large-cohort validation to date. The biology of LRRIQ3 in opioid circuitry remains incompletely characterized.

Practical Actions

Carriers of one or two T alleles (approximately 54% of people of European descent) face a modestly elevated statistical signal for opioid misuse behavior. This does not predict addiction — it reflects a polygenic background that, combined with environmental and clinical factors, may influence how opioid prescriptions are experienced and used. For people with this variant who are prescribed opioids for pain, the most actionable response is to establish clear communication with prescribers, use non-opioid analgesic strategies as first-line where effective, and monitor for early signs of escalating use.

Interactions

The Sanchez-Roige GWAS also identified a second genome-wide significant locus, rs3791033 in KDM4A (a histone demethylase). The genetic correlation with opioid use disorder (rg = 0.64–0.80) suggests substantial overlap with OPRM1 variants (rs1799971, A118G), which alter mu-opioid receptor binding affinity. Carrying both a reduced-function OPRM1 variant and the rs640561-T allele has not been formally studied as a compound genotype, but the pathways are biologically complementary: one affects receptor sensitivity, the other may affect downstream neural calcium signaling.